Bicuspid Aortic Valve Replacement: Intervention Selection
For bicuspid aortic valve stenosis requiring replacement, surgical aortic valve replacement (SAVR) is the preferred intervention across all age groups, with transcatheter aortic valve implantation (TAVI) reserved only for patients >80 years or those with prohibitive surgical risk.
Age-Based Treatment Algorithm
Patients <65 Years or Life Expectancy >20 Years
- SAVR is recommended 1
- Recent data demonstrate TAVR in patients ≤60 years is associated with 2.5-fold increased 5-year mortality compared to SAVR 2
- In bicuspid anatomy specifically, SAVR shows superior survival with adjusted HR for TAVR mortality of 5.9 (95% CI 2.6-12.9) 3
Valve Type Selection for SAVR:
Age <50 years: Mechanical valve is reasonable if anticoagulation is acceptable 1
- Provides superior durability
- Requires lifelong vitamin K antagonist (VKA) therapy with INR monitoring
- Contraindicated if VKA cannot be managed or is refused
Age 50-65 years: Either mechanical or bioprosthetic is reasonable after shared decision-making 1
- Mechanical: Higher bleeding risk but no reoperation
- Bioprosthetic: Higher reoperation rate (structural deterioration) but no anticoagulation
Age >65 years: Bioprosthetic valve is reasonable 1
- Only 10% structural deterioration at 15-20 years
- Avoids anticoagulation risks in older patients
Patients 65-80 Years
- Either SAVR or transfemoral TAVI is recommended after shared decision-making 1
- Balance expected longevity against valve durability
- However, for bicuspid anatomy, SAVR remains preferred given TAVI's increased complications 3, 4
Patients >80 Years or Life Expectancy <10 Years
- Transfemoral TAVI is recommended in preference to SAVR 1
- Exception: If anatomy unsuitable for transfemoral approach, consider alternative access or SAVR
Critical Bicuspid-Specific Considerations
Bicuspid anatomy presents unique challenges that favor SAVR:
- TAVI shows 2.6-fold increased pacemaker implantation (19% vs 4%) 3
- 5.8-fold increased paravalvular leak risk 3, 4
- 7.7-fold increased heart failure hospitalizations 3
- Increased risk of patient-prosthesis mismatch 5
- Stroke rates are similar between approaches 3, 4
Anticoagulation Requirements
Mechanical Valves
- Indefinite VKA therapy required 6
- Add antiplatelet therapy (typically aspirin 75-100mg daily)
- Requires regular INR monitoring
- Absolute contraindication if patient cannot comply with monitoring or has contraindications to anticoagulation
Bioprosthetic Valves (SAVR)
- VKA therapy for 3-6 months post-operatively is commonly recommended 6
- Then transition to antiplatelet therapy alone
- No consensus on optimal duration; guidelines vary
Post-TAVI
- Dual antiplatelet therapy (DAPT) is most commonly used 6, 7
- Typical regimen: Aspirin plus clopidogrel for 3-6 months
- Then aspirin monotherapy indefinitely
- Alternative regimens under investigation; no definitive consensus 6
Common Pitfalls to Avoid
Age-based TAVR expansion in young patients: Despite increasing TAVR use in patients <60 years (from 7.2% to 45.7% between 2013-2021), this contradicts guidelines and is associated with worse outcomes 2
Underestimating bicuspid complexity: Bicuspid anatomy is not simply "another indication" for TAVR—it carries substantially higher complication rates that persist even with newer-generation devices 3, 5, 4
Ignoring lifetime valve management: Younger patients need consideration of future coronary access, valve-in-valve feasibility, and cumulative reintervention burden 5, 8
Overreliance on chronological age: Life expectancy, frailty, comorbidities, and patient anatomy matter more than age cutoffs alone 1, 8
Special Consideration: Ross Procedure
For patients <50 years with contraindication to anticoagulation and appropriate anatomy:
- Ross procedure may be considered at a Comprehensive Valve Center 1
- Avoids prosthetic valve and anticoagulation
- Risk: Both neoaortic valve and pulmonic homograft require reintervention within 10-20 years
- Reserved for highly selected patients with experienced surgeons